Andrew Nava's  Instablog

Andrew Nava
Send Message
Andrew Nava LLC is a healthcare focused consulting and investment firm. Prior to launching Andrew Nava LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical,... More
My company:
Andrew Nava, LLC
  • Biotech Milestones and Database Updates for July 6, 2010 0 comments
    Jul 6, 2010 11:25 AM | about stocks: ASTX, ENDP, UTHR, MIPI, IPCI, DRRX, MYRX

    Below is a sample morning note to clients, which includes new catalysts/milestones added to our database, as well as companies and products that have new data.

    Dear Sample Client,


    ENDP: Submitted Complete Response to Fortesta 2009 CRL on July 1, 2010 (Class 2 Resubmission), expected FDA approval January 1, 2011; response contained re-analysis of the primary variable (testosterone levels) in the original pivotal study and plans for a post-approval "hand-wash" study.

    SUPG: Eisai plans to submit Dacogen sNDA for elderly AML by March 31, 2011 (based on secondary endpoints, did not meet primary endpoint)


    UTHR, MIPI, IPCI, DRRX, Picoplatin, MGCD265, mocetinostat, Azixa, MPC-3100

    RESEARCH - BPAX, AVII, CORT, EXAS (ask about our rates)

    Andrew Nava LLC provides equity research services for both institutional and retail healthcare investors. We focus on fundamental research of small- to mid-cap healthcare companies with the potential for significant market cap appreciation in the next 6-12 months. Our investment theses are based on event-driven catalysts and value-driven growth.

    Institutional services include contract analyst work, generation of trading and investing ideas, and reports on companies within our coverage universe. Our extensive relationships with company management, analysts, KOLs and industry professionals provide the insight which drives our research. With the exception of institutional consulting and contract work, retail clients have access to the same information that our institutional clients do.

    Our research is powered by our database. Information is derived exclusively from public sources and is useful for tracking clinical trial data and upcoming company milestones. As of June 2010, the database covers over 290 publicly-traded biotechnology and pharmaceutical companies, more than 1000 profiles of approved and development-stage drugs, devices and diagnostics, and 17 different catalyst types.

    For more information, please visit

    Disclosure: No positions

Back To Andrew Nava's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.